← Search & browse all drugs

gadobenic acid

V08CA08

Forms & Strengths

Injectable solution 0.5 mmol/mL (0.5 M) gadobenate dimeglumine
Vial 1 mL and 5 mL presentations for IV use

Adult Dosing

0.1 mmol/kg IV bolus (0.2 mL/kg) for routine MRI/MRA
Up to 0.2 mmol/kg IV for enhanced hepatic imaging
Inject at rate ≤2 mL/sec; flush with saline

Pediatric Dosing

0.1 mmol/kg IV bolus (0.2 mL/kg) for children ≥1 month
Neonates and infants may receive 0.05‑0.1 mmol/kg based on clinical judgment
Maximum single dose 0.2 mmol/kg for hepatic studies

Indications

Contrast enhancement for CNS MRI and MR angiography
Contrast for breast MRI
Hepatobiliary imaging (dynamic & delayed phase)
Cardiac MRI and MRA
Pediatric MRI when contrast is required

Mechanism of Action

Paramagnetic gadolinium chelate that shortens T1 relaxation of nearby water protons
Partial hepatocyte uptake allows combined vascular and hepatobiliary phase imaging
Rapid renal excretion; ~95% eliminated via kidneys, ~5% via bile

Contraindications

History of severe allergic reaction to gadobenic acid or any GBCA
Severe renal impairment (eGFR <30 mL/min/1.73 m²) due to NSF risk
Pregnancy only if essential; avoid elective use

Adverse Reactions

Nausea, vomiting, headache
Injection site pain or warmth
Mild pruritus or rash; rare anaphylactoid reactions
Nephrogenic systemic fibrosis in high‑risk renal patients
Gadolinium retention‑related symptoms (arthralgia, fatigue)

Drug Interactions

Concurrent use of other GBCAs may increase cumulative gadolinium load
Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) heighten NSF risk
Caution with ferumoxytol as it may reduce MRI contrast efficacy

Curated Content: Needs Vetting Before Put to Clinical Use